Cancer treatments have been, and continue to be in most cases, based on the organ site where the tumor originates—some treatments are specific for breast cancer, some for lung cancer, and so on. However, rapid advances in genomic sequencing technologies have led to a recent development that deviates from the long-held notion of treating cancers based on the site of origin.Read More
The American Association for Cancer Research (AACR) began publishing scientific articles in 1916, and now proudly publishes eight peer-reviewed journals which cover a diverse array of cancer-related topics. The editors …Read More
Anthracyclines, a widely used class of chemotherapeutics, work in several ways to kill rapidly dividing cells, including those found in a tumor. While these drugs are commonly used to treat many types of adult and childhood cancer, they have a detrimental side effect – cardiotoxicity.
The cardiotoxicity of anthracyclines is dose-dependent; the more exposure patients have to the drug, the more serious risk they carry for heart-related problems. This can represent a unique challenge in children treated with anthracyclines, whose hearts are still developing.Read More
Biopsies have been an integral part of cancer care for decades. In undiagnosed patients, oncologists can examine suspicious tissues and determine if the cells are benign or malignant. Following diagnosis, biopsies can reveal additional information about a patient’s tumor – What mutations are driving this cancer? Is this patient likely to respond to a particular therapy? In cases of cancer recurrence, biopsies can provide further information – Has this patient become resistant to treatment? Is the tumor driven by different mutations?Read More
Each month, the American Association for Cancer Research (AACR) publishes 10 articles from its eight esteemed scientific journals, showcasing some of the leading discoveries in cancer research. Read on to learn about the editors’ selections from this month. All articles featured are freely available for a limited time.Read More
The American Association for Cancer Research (AACR) publishes eight esteemed scientific journals. Each month, these journals feature a wide range of peer-reviewed research that encompasses the entire spectrum of cancer science. Some of the world’s leading cancer scientists publish articles in our journals, contributing greatly toward the AACR’s mission to prevent and cure cancer through research, education, communication, and collaboration.
We are pleased to debut a new feature on the blog, Editors’ Picks. Each month, AACR journal editors will share a curated list of original articles, representing each publication. While our journals are subscription-based, the stories featured in Editors’ Picks will be freely available for the month.Read More
This week, President Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which is aimed at supporting pediatric cancer research. The legislation calls for expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.Read More
Assessing new anticancer therapeutics in clinical trials is a vital step in evaluating the toxicity and efficacy of treatment before its approval for widespread use. Throughout these trials, many patients encounter a variety of side effects, ranging from physical ailments such as nausea or rash to psychological symptoms such as depression or anxiety. While it is standard practice to record clinician-reported outcomes to characterize safety, there is no current standard requirement for the use of patient-reported outcomes (PROs) in cancer clinical trials.Read More
Skin cancer is the most commonly diagnosed cancer in the United States. Every year, about 5 million Americans are treated for various forms of the disease.
Skin cancer types include basal and squamous cell cancers, as well as melanoma, the deadliest form of skin cancer. About 73,870 Americans are expected to be diagnosed with melanoma this year. Survival rates are significantly higher when the disease is diagnosed at its earliest stage.Read More
Multiple myeloma arises in immune cells called plasma cells. It is one of the most commonly diagnosed hematological malignancies in the United States, with more than 30,000 new cases expected in 2018.Read More